New York, March 2, 2026, 18:05 EST — After-hours
- Eli Lilly (LLY) shares were last down about 3.2% at $1,017.97.
- The company says it could launch its oral obesity drug orforglipron as early as the second quarter, pending an FDA decision expected in April.
- Investors are also weighing U.S. drug-pricing pressure and intensifying competition in weight-loss medicines.
Eli Lilly and Company (LLY) shares were last down 3.2% in after-hours trading at $1,017.97 on Monday, after falling in the regular session.
The stock move landed as the drugmaker pressed investors to focus on its next big obesity catalyst: orforglipron, a daily pill that targets GLP-1, a gut hormone that helps control appetite and blood sugar. Lilly’s valuation has become tightly linked to how fast it can scale weight-loss medicines and defend pricing.
That matters now because payers and politicians are pressing for lower drug bills, even as demand for weight-loss treatments stays strong. Even small shifts in coverage or discounts can move profit forecasts.
Chief Financial Officer Lucas Montarce told the TD Cowen healthcare conference Lilly expects orforglipron could reach the U.S. market “as early as Q2” if the FDA signs off in April. He said Lilly could start shipping within about a week of approval and is already talking with pharmacy benefit managers — the middlemen that negotiate coverage and rebates — about access. 1
Lilly’s shares closed down 3.23% and lagged a flat S&P 500 session, leaving the stock about 10% below its Jan. 8 52-week high, MarketWatch reported. Trading volume was roughly in line with its recent average, the report said. 2
Competition is tightening, and pricing nerves keep resurfacing. Novo Nordisk said last week it will cut U.S. list prices for Ozempic and Wegovy to $675 a month from Jan. 1, 2027 — a move Citi analyst Geoffrey Meacham said would likely touch only a small slice of new prescriptions compared with the cash-pay market, where patients pay out of pocket. Bernstein’s Courtney Breen called it “not the beginning of a price war.” 3
In Washington, the Trump administration is now asking smaller drugmakers to negotiate lower prices for Medicaid after 16 large companies including Lilly struck deals, Reuters reported. CMS said it extended the application deadline for its new payment model to April 30 and will begin meetings with interested manufacturers on April 1; Innovation Center director Abe Sutton said the move would give firms more room to participate and “lower costs to the Medicaid program.” 4
Investors are trying to map how those pushes filter into the obesity market, where list prices and net prices can diverge sharply after rebates. PBMs and insurers decide which drugs get preferred placement, and that can steer patients long before a list price change shows up.
Lilly also has work to do on tolerability. Full results from a head-to-head diabetes trial published last week showed more patients on the highest dose of orforglipron reported stomach-related side effects and stopped treatment than those on Novo’s oral semaglutide; Lilly cardiometabolic president Kenneth Custer said he sees the profile as “a trade-off” patients will accept for better glucose control and weight loss. 5
For now, traders are watching for any hint the FDA review slips, and for signs Lilly can lock in broad coverage ahead of launch. A fast rollout would test manufacturing and distribution, but also the willingness of payers to cover another expensive obesity drug.
The next clear catalysts are an FDA decision expected in April and Lilly’s scheduled first-quarter earnings call on April 30. 6
